CytoCore Reports First Quarter Progress

Revenues up 109% Year-over-Year
Operating Expenses Decreased by 38%
Net Loss Decreased 23% Year-Over-Year
CHICAGO--(Business Wire)--
CytoCore Inc. (OTCBB:CYOE), the developer of a suite of
cost-effective cervical cell collection devices for the early
detection of cancer and sexually transmitted diseases, today reported
good progress during its first quarter ended March 31, 2008.

"During the first quarter we continued our ongoing progress in our
marketing and sales efforts," said Robert McCullough, Jr., chief
executive officer of CytoCore, Inc. "We received approval from the
U.S. Food & Drug Administration (FDA) for our SoftPAP(TM) Cervical
Cell Collector, we launch our revolutionary collection device at the
American College of Obstetricians and Gynecologist annual meeting in
May in New Orleans, and we signed our first U.S. distribution
agreement with CoMedical, Inc. We have received our first order and
began shipment in April of 2008."

Advances for CytoCore Solutions(TM) include: the continued
progress with key clinical trials; the Collector Colposcopy trial
reached its 650-patient objective in May, and results are expected in
the latter half of 2008. Continued development of a cytological
endometrial cancer screening assay for use in conjunction with the
AIPS platform is continuing.

CytoCore has expanded its international distribution agreement to
include Switzerland. The company received its first order in April
from the region and began shipment. "We are making good progress in
Europe. We are producing and shipping in quantities responsive to
expanding worldwide demand - in line with CytoCore's overall business
plan and marketing goals," added Mr. McCullough.

The company continues its focus on high volume, higher-end
physician practices, and has hired Eric Cohill as senior vice
president responsible for U.S. sales and marketing. The company signed
its first U.S. distribution agreement with CoMedical for SoftPAP and
will leverage CoMedical's relationship with targeted healthcare
professionals in the Pacific Northwest.

"Our achievements this quarter are consistent with the goals we
articulated at year-end in 2007. As a result of our execution, we have
established CytoCore as an institutional quality investment and were
able to raise $10 million in new equity financing. We have positioned
ourselves for continued growth with medical screening and other
devices that respond directly to well-documented global health crises
such as the epidemic of HPV infection among young women in the United
States and abroad," Mr. McCullough concluded.

Financial Highlights for the First Quarter Ended March 31, 2008

Revenues increased $24,000, or 109% to $46,000 compared with
$22,000 in the same period last year. This increase was the result of
sales of the company's SoftPAP cervical collection device totaling
$28,000 during the quarter, partially offset by a reduction in revenue
of $6,000 from the licensing fees for our slide-based installed
system.

Selling, general and administrative expenses decreased 38% to $1.1
million compared with $1.7 million in the first quarter of 2007. The
reduction in SG&A expenses was partially offset by increases in
advertising and marketing costs related to our SoftPAP product and
other professional fees.

Net loss for the quarter, before preferred dividends, decreased
23% to $1.9 million compared with $2.5 million in the same period in
2007. This decrease was partially offset by increases in research and
development and SG&A expenses due to the expansion in operations.

About CytoCore Inc.

CytoCore develops cost-effective, highly accurate screening
systems for early detection of gynecological cancers and sexually
transmitted diseases. Designed for easy deployment at a laboratory or
at the point-of-care, the CytoCore suite of sample collection
technologies assists in the detection of cervical, endometrial, and
other cancers, as well as the human Papilloma virus. The CytoCore
Solutions(TM) System is being developed to provide medical
practitioners with highly accurate, low-cost, cervical and uterine
cancer screening systems that can be seamlessly integrated into
existing medical models. More information is available at:
www.CytoCoreInc.com.

Certain statements in this release are forward-looking. These
statements are based on CytoCore's current expectations and involve
many risks and uncertainties, such as the company's inability to
obtain sufficient financing, the possibility that clinical trials will
not substantiate CytoCore's expectations with respect to the CytoCore
Solutions(TM) System, and other factors set forth in reports and
documents filed by CytoCore with the Securities and Exchange
Commission. Actual results may differ materially from CytoCore's
current expectation depending upon a number of factors affecting the
Company's business. These factors include, among others, risks and
uncertainties detailed in the Company's periodic public filings with
the Securities and Exchange Commission, including but not limited to
the Company's Annual Report on Form 10-KSB for the year ended December
31, 2007. Except as expressly required by law, CytoCore undertakes no
obligation to publicly update or revise any forward-looking statements
contained herein.

CytoCore, Inc.
Robert McCullough, Jr., 312-222-9550
or
EVC Group
Dahlia Bailey or Matthew Selinger, 415-896-6820
mselinger@evcgroup.com

Copyright Business Wire 2008